Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R1

FGF R1

Brief Information

Name:Fibroblast growth factor receptor 1
Target Synonym:FGFBR,bFGF-R-1,EC:2.7.10.1,EC 2.7.10,FLG,FLT2,CEK,BFGFR,Proto-oncogene c-Fgr,Fibroblast growth factor receptor 1,CD331,FGFR1,Basic Fibroblast Growth Factor Receptor 1,Fms-Related Tyrosine Kinase 2,FGFR-1,FLT-2,HBGFR,Heparin-Binding Growth Factor Receptor,FMS-Like Tyrosine Kinase 2,Hydroxyaryl-Protein Kinase,FGFR1/PLAG1 Fusion,Pfeiffer Syndrome,CD331 Antigen,EC 2.7.10.1,HRTFDS,N-Sam,ECCL,KAL2,HH2,OGD,Receptor, Fibroblast Growth Factor, Type 1
Number of Launched Drugs:9
Number of Drugs in Clinical Trials:26
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FG1-H5223 Human Human FGF R1 / CD331 Protein, His Tag (SPR verified)
FG1-H5223-structure
FG1-H5223-sds
ACRO Quality

Part of Bioactivity data

FG1-H5223-MALS-HPLC
 FGF R1 SPR

Human FGF R1, His Tag (Cat. No. FG1-H5223) captured on CM5 chip via anti-His antibody can bind Human FGF acidic, Tag Free (Cat. No. AFF-H4116) with an affinity constant of 55.9 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Synonym Name

FGFR1,BFGFR,CD331,CEK,FGFBR,FLG,HBGFR,N-SAM,FLT2,H2,KAL2,FLJ14326

Background

Fibroblast growth factor receptor 1 (FGFR1) is also known as basic fibroblast growth factor receptor 1(BFGFR1), FMS-like tyrosine kinase, CD331, and is a receptor tyrosine kinase whose ligands are specific members of the fibroblast growth factor family. This protein is one of several fibroblast growth factor receptors, which are related proteins that are involved in important processes such as cell division, regulation of cell growth and maturation, formation of blood vessels, wound healing, and embryonic development.The FGFR1 protein spans the cell membrane, so that one end of the protein remains inside the cell and the other end projects from the outer surface of the cell. This positioning allows the FGFR1 protein to interact with specific growth factors outside the cell and to receive signals that help the cell respond to its environment. When growth factors attach to the FGFR1 protein, the receptor triggers a cascade of chemical reactions inside the cell that instruct the cell to undergo certain changes, such as maturing to take on specialized functions. The FGFR1 protein is thought to play an important role in the development of the nervous system. This protein may also help regulate the growth of long bones, such as the large bones in the arms and legs.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Infigratinib BGJ-398; NVP-BGJ398 Approved Novartis Pharma Ag TRUSELTIQ United States Cholangiocarcinoma Helsinn Healthcare Sa 2021-05-28 Nasopharyngeal Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Glioma; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Gastrointestinal Stromal Tumors; Oropharyngeal Neoplasms; Cholangiocarcinoma; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Colonic Neoplasms; Biliary Tract Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Achondroplasia; Papillomavirus Infections; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Hematologic Neoplasms; Solid tumours Details
Futibatinib TAS-120 Approved Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd LYTGOBI United States Cholangiocarcinoma Taiho Oncology Inc 2022-09-30 Solid tumours; Bone Marrow Neoplasms; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Sarcoma; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef EU systemic sclerosis-associated interstitial lung disease Boehringer Ingelheim International Gmbh 2014-10-15 Gliosarcoma; Breast Neoplasms; Sarcoma; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Genital Neoplasms, Female; Silicosis; Prostatic Neoplasms; Carcinoma, Squamous Cell; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colonic Neoplasms; Ovarian Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoid Tumor; Endometrial Stromal Tumors; Carcinoma, Renal Cell; Radiation Pneumonitis; Neoplasms; Idiopathic Pulmonary Fibrosis; Solid tumours; Scleroderma, Systemic; Glioblastoma; Small Cell Lung Carcinoma; Mesothelioma; Neuroendocrine Tumors; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Asbestosis; Oligodendroglioma Details
Lenvatinib Mesylate ER-203492-00; E-7080; MK-7902 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 Japan Carcinoma, Renal Cell Merck Sharp & Dohme Corp 2015-02-13 Liver Diseases; Paraganglioma; Neoplasm Metastasis; Thyroid Cancer, Papillary; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Osteosarcoma; Cholangiocarcinoma; Breast Neoplasms; Solid tumours; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Kidney Diseases; Neoplasms; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Pheochromocytoma; Renal Insufficiency; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Fallopian Tube Neoplasms; Esophageal adenocarcinoma; Adenoma; Thyroid Neoplasms; Lung Neoplasms; Thymoma; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Carcinoma, Islet Cell; Ovarian Neoplasms; Liver Neoplasms; Hemangiosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Carcinoid Tumor; Insulinoma; Solid tumours; Colonic Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Transitional Cell; Carcinoma, Adenoid Cystic; Glucagonoma Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Thyroid Neoplasms Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Esophageal Squamous Cell Carcinoma; Bone Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Gastrointestinal Stromal Tumors; Urologic Neoplasms; Sarcoma, Alveolar Soft Part; Endometrial Neoplasms; Gallbladder Neoplasms; Bile Duct Diseases; Thyroid Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Osteoma; Small Cell Lung Carcinoma; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Drug-Related Side Effects and Adverse Reactions; Ovarian Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Leiomyosarcoma; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Carcinoma, Ovarian Epithelial; Sarcoma, Synovial; Neuroendocrine Tumors; Liver Diseases; Sarcoma; Medullary thyroid cancer (MTC); Nasopharyngeal Carcinoma Details
Surufatinib HMPL-012 Approved Hutchison Medipharma Ltd 苏泰达, SULANDA Mainland China Neuroendocrine Tumors Hutchison Medipharma Ltd 2020-12-29 Biliary Tract Neoplasms; Hematologic Neoplasms; Solid tumours; Intestinal Neoplasms; Kidney Diseases; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Small Cell Lung Carcinoma; Neuroendocrine Tumors; Sarcoma; Hepatic Insufficiency; Bile Duct Neoplasms; Carcinoma, Neuroendocrine; Thyroid Neoplasms; Appendiceal Neoplasms Details
Erdafitinib 890E37NHMV; JNJ-42756493; G-024; JNJ-493 Approved Astex Pharmaceuticals Inc Balversa South Korea Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Neoplasms, Neuroepithelial; Osteosarcoma; Neuroblastoma; Breast Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Histiocytic Sarcoma; Bile Duct Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Sarcoma; Glioma; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Xanthogranuloma, Juvenile; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive, Peripheral; Rhabdoid Tumor; Hematologic Neoplasms; Rhabdomyosarcoma; Ependymoma; Medulloblastoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Hepatoblastoma; Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Wilms Tumor; Multiple Myeloma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Histiocytosis, Langerhans-Cell; Sarcoma, Ewing Details
Pazopanib Hydrochloride GSK-786034; GW-786034B; SB-786034; GW-786034 Approved Glaxosmithkline Plc, Novartis Pharma Ag 维全特, Armala, Votrient, Patorma Mainland China Carcinoma, Renal Cell Novartis Pharma Schweiz Ag 2009-10-19 Peritoneal Neoplasms; Lymphoma; Uterine Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Thyroid Neoplasms; Gastrointestinal Stromal Tumors; Gliosarcoma; Carcinoma, Mucoepidermoid; Genital Neoplasms, Female; Uterine Cervical Diseases; Choriocarcinoma; Colorectal Neoplasms; Neuroblastoma; Osteosarcoma; Gastrinoma; Psoriasis; Brain Neoplasms; Urethral Neoplasms; Breast Neoplasms; Medullary thyroid cancer (MTC); von Hippel-Lindau Disease; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Endodermal Sinus Tumor; Neoplasms, Germ Cell and Embryonal; Paraganglioma; Thyroid Cancer, Papillary; Neoplasm Metastasis; Uterine Cervical Neoplasms; Breast Neoplasms, Male; Prostatic Neoplasms; Macular Degeneration; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Glioma; Germinoma; Carcinoma, Neuroendocrine; Carcinoma, Embryonal; Carcinoma, Squamous Cell; Telangiectasia, Hereditary Hemorrhagic; Thyroid Carcinoma, Anaplastic; Neoplasms; Carcinoid Tumor; Herpes Genitalis; Pheoc Details
Pemigatinib INCB-054828; INCB-54828; IBI-375 Approved Incyte Corp Pemazyre, 伯坦, 达伯坦 Mainland China Biliary Tract Neoplasms Innovent Biologics(Suzhou) Co Ltd 2020-04-17 Translocation, Genetic; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Glioma; Lung Neoplasms; Endometrial Neoplasms; Bile Duct Neoplasms; Colitis, Ulcerative; Urologic Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Solid tumours; Multiple Myeloma; Urinary Bladder Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Myeloproliferative Disorders; Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Biliary Tract Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
CPL-304110 CPL-304110; CPL-304-110 Celon Pharma Sa Details
R-1530 RG1530; R-1530; RG-1530 F. Hoffmann-La Roche Ltd Details
LY-2874455 LY-2874455 Eli Lilly And Company Details
TT-00434 TT-00434 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours; Urinary Bladder Neoplasms Details
ODM-203 ODM-203 Orion Corp Details
Fazpilodemab RG-7992; BFKB-8488A; RO-7040551 Genentech Inc Details
SC-0011 SC-0011 Phase 1 Clinical Shijiazhuang Zhikang Hongren New Drug Development Co Ltd Solid tumours Details
Efruxifermin AKR-001; AMG-876; EFX Phase 2 Clinical Amgen Inc Non-alcoholic Fatty Liver Disease; Diabetes Mellitus Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 2 Clinical Arqule Inc Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Zoligratinib CH-5183284; FF-284; Debio-1347 Phase 2 Clinical Chugai Pharmaceutical Co Ltd Solid tumours; Breast Neoplasms Details
NGM-313 NGM-313; MK-3655 Phase 2 Clinical Ngm Biopharmaceuticals Inc Non-alcoholic Fatty Liver Disease; Hepatitis; Obesity Details
DR-10624 DR-10624 Phase 1 Clinical Zhejiang Doer Biologics Corp Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Obesity; Diabetes Mellitus Details
HH185 3-D185; HH-185; 3D185; 3D-185 Phase 2 Clinical Shanghai Medicilon Inc, ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours; Cholangiocarcinoma Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Solid tumours; Head and Neck Neoplasms; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
Rogaratinib BAY-1163877 Phase 2 Clinical Bayer AG Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Non-Small-Cell Lung Details
Tasurgratinib E-7090 Phase 2 Clinical Eisai Co Ltd Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency Details
HMPL-453 HMPL-453 Phase 2 Clinical Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma; Bile Duct Neoplasms Details
ABSK-121 ABSK121; ABSK121-NX Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
AUP1602-C AUP-16; AUP1602-C Phase 2 Clinical Aurealis Diabetic Foot Details
Brivanib Alaninate ZL-2301; BMS-540215; BMS-582664 Phase 2 Clinical Bristol-Myers Squibb Company Carcinoma, Squamous Cell; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Adenocarcinoma; Endometrial Neoplasms; Liver Neoplasms; Colorectal Neoplasms; Sarcoma; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Carcinoma, Renal Cell; Rectal Neoplasms; Solid tumours Details
AZD-4547 AZD-4547; ABSK-091; AZD4547; ABSK091 Phase 2 Clinical Astrazeneca Plc Uterine Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Endometrial Neoplasms; Lung Neoplasms; Multiple Myeloma; Thyroid Neoplasms; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Uterine Cervical Neoplasms; Melanoma; Foodborne Diseases; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Esophageal Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Skin Neoplasms; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Urinary Bladder Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message